| Price | $15.06 |
| Year Range | $15.06 – $32.23 |
| Market Cap | $890M |
| Industry | Biotechnology |
What Is Aktis Oncology’s AI Stock Analysis?
Aktis Oncology’s AI stock analysis on AltIndex combines the company’s fundamentals, price technicals and 25+ alternative data signals — like hiring, web traffic, app downloads and online sentiment — into a single AI Score from 0 to 100 and a plain-English Buy, Hold or Sell read. Unlike a traditional analyst rating that updates a few times a year, the AI Score refreshes as new data arrives, so it tracks Aktis Oncology’s momentum in near-real time.
Aktis Oncology (AKTS) has an AltIndex AI Score of 52/100, currently a Hold signal. The AI Score distills Aktis Oncology's fundamentals, price technicals and 25+ alternative data signals into a single 0–100 rating, so a rising score reflects strengthening data across the board and a falling score the opposite.
Aktis Oncology’s Full AI Analysis
Keep reading AltIndex’s full AI analysis of Aktis Oncology — the fundamental, technical and alternative-data breakdown and the recommendation.
Sign up to read the full analysisWhat’s Driving AKTS’s AI Score?
Fundamentals
Revenue for the last quarter was $3.4M. This is an increase of 4.87% compared to the quarter before it, which is a positive sign of growth. Compared to the same quarter last year, there is an increase of 133.86%, suggesting positive year-over-year growth. Net income for the last quarter was $-24M. This represents a decrease of 31.75% compared to the quarter before it, indicating a need for concern. However, compared to the same quarter last year, there is a decrease of 61.12%, which may be a cause for concern. In the last couple of months, there's been a couple of company insiders selling their stock, a potentially bearish signal.
See Aktis Oncology’s earnings and insider transactions.
Technicals
Today's stock price is $15.06. This represents a decrease of 33.69% compared to a month ago, which may be concerning in the short-term. However, compared to a year ago, there is a decrease of 32.77%, which could be a cause for long-term concern. The trend is bearish. The current SMA10 is $17.17, which is lower than the previous SMA10 of $17.45. This suggests a potential downward trend in price movement. The RSI is 45.3, indicating a neutral condition.
See the full technical analysis and price prediction.
Alternative data
Aktis Oncology has an estimated 5 open positions and this number has been stable over the last couple of months indicating a company in a stable position. Aktis Oncology has an estimate of 4,000 visitors to their webpage, with no meaningful increase or decrese in the last couple of months.
Explore Aktis Oncology’s job postings, web traffic and app downloads.
Frequently Asked Questions: Aktis Oncology AI Stock Analysis
Aktis Oncology's AltIndex AI Score is 52/100, currently a Hold signal. The AI Score blends fundamentals, technicals and 25+ alternative data signals into a single rating from 0 to 100.
AltIndex's AI Score model rates Aktis Oncology a Hold (52/100). This is a data-driven signal, not investment advice — review the breakdown above and combine it with your own research.
The AI Score is generated from fundamental data (earnings, valuation), technical indicators (price trend and momentum), and alternative data signals such as hiring, web traffic, app downloads and sentiment. AltIndex weighs these into a single 0-100 score; the exact weighting is proprietary.
AltIndex generates a complete written AI analysis of Aktis Oncology — company overview, fundamentals, technicals and alternative data, with a recommendation. See the AKTS AI Score or sign up to read the full thesis.
